Direct Medical Care Costs Among Pegylated Interferon Plus Ribavirin-Treated and Untreated Chronic Hepatitis C Patients

Solomon, Matthew D.; Bonafede, Machaon; Pan, Ko-Yu; Wilson, Kathleen; Beam, C; Chakravarti, Paula; Spiegel, Brennan

doi:10.1007/s10620-011-1802-z

Cited by 18 publications

(14 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With respect to the international literature, our study findings are also consistent with the study by Solomon et al, which highlights the cost increase in the management of advanced liver disease, reaching €35,000 in the first year of liver transplant [30]. However, the range of costs for liver transplant varies significantly, with the study by Younossi et al providing an estimate of $168,643…”

Section: Discussionsupporting

confidence: 91%

Managing Hepatitis C Patients in Greece: A Budget Impact Analysis of Simeprevir plus Pegylated Interferon/Ribavirin Regimen at Early Stages of the Disease

Geitona¹,

Kousoulakou²,

Goulis³

et al. 2017

Health

View full text Add to dashboard Cite

Objectives: To identify local resource use such as pharmaceutical treatment, medical follow-up, and patient hospitalization and estimate the budget impact of simeprevir (SMV) plus pegylated interferon (P)/ribavirin (R) as a treatment option in the early stages of the disease in Greece. Methods: A budget impact tool was developed with a two-year time horizon, which estimated the impact on the Social Insurance Funds (SIFs) of introducing SMV + PR in the management of the early disease stages. Total direct and indirect costs were estimated for each of the following health states: non-cirrhotic chronic Hepatitis C (and within that by fibrosis stage), compensated cirrhosis, decompensated cirrhosis, and hepatocellular carcinoma. Data gaps on treatment algorithms, resource use and productivity losses were covered via an expert panel of eight leading hepatologists. Epidemiology data were taken from the published literature. Unit costs were obtained from the Ministry of Health and SIFs. The perspective was that of the SIF and the cost base year was 2015. Results: The total (direct and indirect) cost per patient per year (excluding cost of antiviral treatment) was estimated at €647, €703, €5,753, €16,313 and €37,237 for non-cirrhotic CHC, compensated cirrhosis, decompensated cirrhosis, HCC and liver transplantation, respectively. The budget impact analysis showed that

show abstract

Section: Discussionsupporting

confidence: 91%

Managing Hepatitis C Patients in Greece: A Budget Impact Analysis of Simeprevir plus Pegylated Interferon/Ribavirin Regimen at Early Stages of the Disease

Geitona¹,

Kousoulakou²,

Goulis³

et al. 2017

Health

View full text Add to dashboard Cite

show abstract

“…Using a range of HCV treatment costs ranging from the past standard of care ($18,977)[51] to the current standard of care for patients with cirrhosis ($101,380)[32], the overall estimated cost was calculated to be between $43.6 billion and $53.2 billion (85.2% to 104.7% of base case). The model was sensitive to the cost of incarceration when it was varied between $15,873 and $65,300[52]—results ranged from 94.2% to 113.5% of base case value.…”

Section: Resultsmentioning

confidence: 99%

The societal cost of heroin use disorder in the United States

Jiang

Lee

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

ObjectiveHeroin use in the United States has reached epidemic proportions. The objective of this paper is to estimate the annual societal cost of heroin use disorder in the United States in 2015 US dollars.MethodsAn analytic model was created that included incarceration and crime; treatment for heroin use disorder; chronic infectious diseases (HIV, Hepatitis B, Hepatitis C, and Tuberculosis) and their treatments; treatment of neonatal abstinence syndrome; lost productivity; and death by heroin overdose.ResultsUsing literature-based estimates to populate the model, the cost of heroin use disorder was estimated to be $51.2 billion in 2015 US dollars ($50,799 per heroin user). One-way sensitivity analyses showed that overall cost estimates were sensitive to the number of heroin users, cost of HCV treatment, and cost of incarcerating heroin users.ConclusionThe annual cost of heroin use disorder to society in the United States emphasizes the need for sustained investment in healthcare and non-healthcare related strategies that reduce the likelihood of abuse and provide care and support for users to overcome the disorder.

show abstract

“…The resulting economic burden is multiplied in cases of advanced liver disease, in which complications due to chronic HCV have been established. 5 A recently published cost-ofillness study from Greece assessed the economic burden of HCV at different stages of the disease. 6 The estimated mean direct cost per patient in those without cirrhosis was €642/y (€1 ¼ US $1.30).…”

Section: Introductionmentioning

confidence: 99%

“…7 Costs related to the management of severe liver disease appeared to increase significantly, ranging from €5934/y 5 in patients with decompensated cirrhosis to 4€35,000/y in the first year after liver transplantation. 5 HCV is a "clever" virus, taking advantage of the host to replicate at 10 13 new virions per day, resulting in diverse genetic types. So, in addition to the natural selection process, 6 different genotypes exist and have been studied.…”

Section: Introductionmentioning

confidence: 99%

Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis

Athanasakis

Ferrante

Kyriopoulos

et al. 2015

Clinical Therapeutics

View full text Add to dashboard Cite

Direct Medical Care Costs Among Pegylated Interferon Plus Ribavirin-Treated and Untreated Chronic Hepatitis C Patients

Abstract: Total HCV-related medical costs are higher for treated than untreated patients, driven mostly by higher outpatient pharmacy costs, which outweigh higher HCV-related inpatient costs incurred by untreated patients.

Cited by 18 publications

References 19 publications

Managing Hepatitis C Patients in Greece: A Budget Impact Analysis of Simeprevir plus Pegylated Interferon/Ribavirin Regimen at Early Stages of the Disease

Managing Hepatitis C Patients in Greece: A Budget Impact Analysis of Simeprevir plus Pegylated Interferon/Ribavirin Regimen at Early Stages of the Disease

The societal cost of heroin use disorder in the United States

Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis

Contact Info

Product

Resources

About